The Senate today confirmed Scott Gottlieb, MD, as FDA commissioner by a margin of 57 to 42 votes. The vote came along party lines, with Democratic Senators criticizing Gottlieb’s intertwined connections with the pharmaceutical industry and his opposition to FDA’s risk evaluation and mitigation strategies.
Gottlieb’s predecessor, Robert Califf, MD, who led the FDA for less than a year, has previously expressed his faith in Gottlieb as the FDA head.
Welcoming Gottlieb’s nomination, Rep. Greg Walden (R-OR.), chairman of the House Energy and Commerce Committee, and Rep. Michael C. Burgess (R-TX), said in a statement, ““We are at a critical juncture in the effort to help accelerate the discovery, development, and delivery of new cures and treatments, and Scott will be an important ally in that journey.”
An important task for the incoming leader of the FDA is to meet the Trump administrations goals of speeding up the drug approval process and also to implement the provisions of the 21st Century Cures Act. The challenges would be to bring about these changes on a very tight budget.
Meanwhile, several organizations, including the American Society of Clinical Oncology (ASCO) and the American College of Rheumatology (ACR) have expressed their support for Gottlieb’s confirmation.
“As a physician and cancer survivor, Dr Gottlieb knows firsthand that safe and effective cancer treatments must move from the lab to the patient as quickly as possible. We are hopeful that Dr Gottlieb will serve as a passionate advocate for the public’s health,” said Daniel F. Hayes, MD, FACP, FASCO, president of ASCO, in a statement.
In his statement congratulating Gottlieb, Sharad Lakhanpal, MBBS, MD, president of ACR said, “The FDA continues to play a critical role in lowering biologic drug costs as it works to bring safe, effective, and lower-cost biosimilar alternatives to the marketplace. Therefore, it is imperative that FDA have the funding and resources it needs to expedite biosimilar drug approvals, hire and retain qualified staff, issue guidance, and perform adequate post-market surveillance.
“We look forward to working with Commissioner Gottlieb, Congressional leaders and the Trump Administration to bolster the FDA’s important work on biosimilars to ensure more Americans can access safe, effective and life-changing therapies.”
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.